6-24-2021

SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms

Christine Vazquez  
*University of Pennsylvania Perelman School of Medicine*

Sydnie E Swanson  
*University of Pennsylvania Perelman School of Medicine*

Seble G Negatu  
*University of Pennsylvania Perelman School of Medicine*

Mark Dittmar  
*University of Pennsylvania Perelman School of Medicine*

Jesse Miller  
*University of Pennsylvania Perelman School of Medicine*

Follow this and additional works at: [https://jdc.jefferson.edu/mifp](https://jdc.jefferson.edu/mifp)

Let us know how access to this document benefits you

See next page for additional authors

**Recommended Citation**

Vazquez, Christine; Swanson, Sydnie E; Negatu, Seble G; Dittmar, Mark; Miller, Jesse; Ramage, Holly; Cherry, Sara; and Jurado, Kellie A, "SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms" (2021). *Department of Microbiology and Immunology Faculty Papers*. Paper 127.

https://jdc.jefferson.edu/mifp/127

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Microbiology and Immunology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Christine Vazquez, Sydnie E Swanson, Seble G Negatu, Mark Dittmar, Jesse Miller, Holly Ramage, Sara Cherry, and Kellie A Jurado
SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms

Christine Vazquez, Sydnie E. Swanson, Seble G. Negatu, Mark Dittmar, Jesse Miller, Holly R. Ramage, Sara Cherry, Kellie A. Jurado

1 Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America, 2 Department Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America, 3 Department of Microbiology and Immunology, Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States of America

* kellie.jurado@pennmedicine.upenn.edu

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, infecting over 43 million people and claiming over 1 million lives, with these numbers increasing daily. Therefore, there is urgent need to understand the molecular mechanisms governing SARS-CoV-2 pathogenesis, immune evasion, and disease progression. Here, we show that SARS-CoV-2 can block IRF3 and NF-κB activation early during virus infection. We also identify that the SARS-CoV-2 viral proteins NSP1 and NSP13 can block interferon activation via distinct mechanisms. NSP1 antagonizes interferon signaling by suppressing host mRNA translation, while NSP13 downregulates interferon and NF-κB promoter signaling by limiting TBK1 and IRF3 activation, as phospho-TBK1 and phospho-IRF3 protein levels are reduced with increasing levels of NSP13 protein expression. NSP13 can also reduce NF-κB activation by both limiting NF-κB phosphorylation and nuclear translocation. Last, we also show that NSP13 binds to TBK1 and downregulates IFIT1 protein expression. Collectively, these data illustrate that SARS-CoV-2 bypasses multiple innate immune activation pathways through distinct mechanisms.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that emerged in Wuhan, China in late 2019 [1]. It is a single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family of viruses. SARS-CoV-2 is the third Coronaviridae virus to emerge into humans and become a public health concern in just the last two decades; following SARS-CoV in 2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 [2, 3]. Infection with SARS-CoV-2 causes Coronavirus Disease-2019 (COVID-19) [4]. Despite drastic efforts to mitigate transmission, SARS-CoV-2 has spread globally and caused COVID-19-related deaths worldwide. There is an urgent need for mechanistic insight into the initial molecular events and host-SARS-CoV-2 interactions that progress toward the inflammatory disease state of COVID-19.
The innate immune antiviral program provides the first barrier of protection against viral pathogens. Upon RNA virus infection, viral pathogen associated molecular patterns (PAMPs), such as viral RNA, are sensed by cytosolic pattern recognition receptors, including RIG-I, MDA5, and TLR family members [5]. RIG-I-viral RNA binding initiates a downstream signaling cascade through a central innate immune adaptor protein, MAVS. Once MAVS is activated, the kinases TBK1 and IKKe phosphorylate IRF3, leading to its nuclear translocation and transcriptional induction of interferon-beta (IFN-β) [6, 7]. Secreted IFN-β binds to the IFN-α/β receptors (IFNAR) on neighboring cells, initiating the interferon response and signaling through the JAK/STAT receptor kinases to produce interferon-stimulated genes (ISGs) [8]. In addition to its role in IFN induction in the RIG-I signaling pathway, TBK1 functions in several other pathways, including inflammation, autophagy, and NF-κB signaling [9]. TBK1 helps facilitate NF-κB signaling by forming a complex with the signaling molecule NEMO and the kinases IKKα and IKKβ. This complex of molecules initiates downstream phosphorylation and ubiquitination events that result in the degradation of the inhibitor of κB (IκB) and subsequent dimerization and translocation of NF-κB [10]. The extensive crosstalk between signaling events elegantly functions to produce ISGs that act to limit viral replication and spread.

RNA viruses, including coronaviruses, have evolved numerous strategies to bypass antiviral signaling programs, including inactivation of viral RNA sensors, transcription factor induction, or through prevention of innate immune protein-protein interactions. For example, MERS-CoV can inhibit PKR, RIG-I, or MDA5 activation through the actions of its accessory protein, protein 4a [11, 12]. SARS-CoV is also able to block IFN signaling through preventing IRF3 dimerization and phosphorylation [13]. TBK1 signaling is a common target for viruses to evade host immune responses. For example, the MERS-CoV protein ORF4b prevents TBK1 interactions with downstream effectors by binding to TBK1 [14, 15]. Additionally, the SARS-CoV M protein can block IRF3 activation through preventing interaction with TBK1 [16]. Coronaviruses have also been found to impede host mRNA translation to reduce IFN signaling. Previous studies have identified a role of the MERS-CoV and SARS-CoV nonstructural protein NSP1 in blocking interferon signaling through inhibiting host protein translation [17–21]. Here, we identify that SARS-CoV-2 blocks immune activation during infection and demonstrate a role for the SARS-CoV-2 proteins NSP1 and NSP13 in blocking IFN and NF-κB activation. Our study corroborates and is wholly consistent with the recently published studies that have identified immune regulatory roles of the SARS-CoV-2 proteins NSP1 and NSP13 [21–26].

Materials and methods

Cell culture

HeLa cells [27] were grown at 37˚C with 5% CO₂ in Dulbecco’s modification of eagle’s medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone), 1% penicillin-streptomycin (Gibco), and 1% Gluta-Max (Gibco). Calu-3 cells (ATCC; HTB-55) were grown at 37˚C with 5% CO₂ in minimum essential medium (MEM; Gibco) supplemented with 10% FBS (Hyclone), 1% penicillin-streptomycin (Gibco), 1% Gluta-Max (Gibco). 293T cells (ATCC; CRL-3216) were grown in DMEM supplemented with 10% FBS (Hyclone) and 1% penicillin-streptomycin (Gibco). All cells were tested and found to be Mycoplasma-free at the Cell Center Services Facility (University of Pennsylvania).

Virus infections

SARS-Related Coronavirus 2, isolate USA-WA1/2020, NR-52281 was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS
CoV-2 virus stocks were propagated in Vero cells. All work with SARS CoV-2 infectious virus (MOI 0.5) was performed in Biosafety Level 3 laboratory and approved by the Penn Institutional Biosafety Committee and Environmental Health and Safety. SeV (Cantell strain; Charles River Laboratories) infections were undertaken in complete media at indicated time points.

**Plasmids and transfections**

The following pLVX- SARS-CoV-2-Strep plasmids obtained from Addgene were used in this study: NSP1 (No 141367), NSP2 (No 141368), NSP4 (No 141369), NSP5 (No 141371), NSP7 (No 141373), NSP8 (No 141374), NSP9 (No 141375), NSP10 (No 141376), NSP11 (No 141377), NSP12 (No 141378), NSP13 (No 141379), NSP14 (No 141380), and NSP15 (No 141381) [28]. Additional plasmids include: pLVX-EGFP-2xStrep (Addgene No 141395), pHA-GE-N-FLAG-HA TBK1 (Addgene No 131791) IFN-Beta_pGL3 (Addgene No 102597), pNL1.1.TK [Nluc/TK] (Promega), p.GL4.45 ISRE-Luc (Promega), and p.GL4.32 NFXb-Luc (Promega). pLVX-nsp1-2xStrep containing either the K164A/H165A (NSP1 KH) or the R125A/K126A (NSP1 RK) mutations were generated using QuickChange site directed mutagenesis (Agilent) with the primers 5’-CTCGCGAGTAACGCCACTGCTAGCTGCCGTATTCCAGTTTT CCGGAAA-3’ and 5’-TTTCCAGGAAAACTGGAATACGGCAGCTAGCAGTGGCGTTACTC GCGAG-3’ (KH) and 5’-CCGCCCCCTGTGTTCCCCTATTGCTGGCACAACGACCTTTCCGAT ATGC-3’ and 5’-GCATACTGGAAGGTTGCTGTGCCGCAAAATGGGAACAGGGGCAGG-3’ (RK).

The sequences of all plasmids were verified by DNA sequence (Genewiz) and are available upon request. Transfections were performed using Polyjet transfection reagent (SignaGen Laboratories) according to manufacturer’s instructions.

**Immunofluorescence and quantification**

HeLa cells were seeded at 1x10^5 cells/mL into 6-well plates and transfected with 1 μg SARS CoV-2 NSP1 WT, SARS-CoV-2 NSP13, SARS-CoV-2 NSP9 or GFP the following day. Twenty-four hours post transfection, cells were infected with SeV by addition of 100 HA units/mL into medium. Six hours post-infection, cells were fixed in 4% paraformaldehyde, permeabilized, and stained. Images were acquired using a Nikon Ti2E scope. Image processing was conducted using Fiji software. Image brightness and contrast were adjusted and cells were counted using the Cell Counter plugin. Strep-tagged SARS-CoV-2 proteins were visualized and counted in the FITC (green) channel, and NF-κB protein was visualized in the TRITC (red) channel. Strep-expressing cells were selected as type 1 and cells with NF-κB-DAPI colocalization were selected as type 2. Counts were then used to calculate the frequency of type 1 to type 2.

**Antibodies**

Antibodies used for immunoblot and immunofluorescence analysis include: rabbit anti-Flag (1:1000, Sigma), mouse anti-Flag M2 (1:1000, Sigma), rabbit anti-IRF3 (1:100 or 1:500, Cell Signaling Technology), mouse anti-IRF3 (1:1000, Cell Signaling Technology) rabbit anti-TBK1 (1:1000, Cell Signaling Technology), rabbit anti-phospho-TBK1 (1:1000, Cell Signaling Technology), rabbit anti-phospho-IRF3 (1:1000, Cell Signaling Technology), rabbit anti-IFIT1 (1:1000, Cell Signaling Technology), human anti-SARS-CoV-2 Spike (CR3022, 1:5000), rabbit anti-SARS-CoV-2 nucleocapsid (Genetex, 1:1000), rabbit anti-NF-κB (1:500, Cell Signaling Technology), rabbit anti-phospho-NF-κB (1:1000, Cell Signaling Technology), mouse anti-Strep (1:1000, Biolegend; 1:1000, Genscript), rabbit anti-Actin (1:1000, Cell Signaling Technology), Streptavidin-HRP (1:1000, Jackson ImmunoResearch), species-specific HRP-Conjugated
antibodies (1:10,000, Jackson ImmunoResearch). Alexa Fluor conjugated secondary antibodies (1:500, Life Technologies), and nuclear counterstain 4',6'-Diamidino-2-phenylindole dihydrochloride- (DAPI; 1:1000, ACROS Organics).

**Immunoblotting**

Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (50mM Tris 10 mM 150 mM NaCl 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 0.02% sodium azide) or passive lysis buffer (Promega) supplemented with complete protease inhibitor cocktail (Sigma), phenylmethylsulfonyl fluoride (PMSF, Millipore), and phosphatase inhibitor (Sigma), with post-nuclear supernatants harvested by centrifugation. Protein concentration was determined by Bradford assay, and 20–30 μg quantified protein was resolved by SDS-PAGE, transferred to Polyvinylidene fluoride (PVDF) membranes using the Trans-Blot Turbo System (Bio-Rad) and blocked with either 3% bovine serum albumin (Sigma) in TBS with 0.1% Tween (TBS-T) or 5% milk in TBS-T. Membranes were probed overnight at 4˚C with specific antibodies against proteins of interest, washed three times with TBS-T, incubated with species-specific HRP-conjugated antibodies (Jackson ImmunoResearch, 1:10,000), washed three times with TBS-T, and treated with Amersham ECL western blotting detection reagent (GE) or SuperSignal West Femto Substrate (Thermo Fisher). Membranes were then imaged using the Amersham Imager 680 (GE).

**Immunoprecipitation**

293T cells were seeded in 10cm plates and transfected with either vector, Flag-TBK1, or co-transfected with Flag-TBK1 and SARS-CoV-2 NSP13 plasmids. Twenty-four hours post transfection, cells were harvested and lysed in IP lysis buffer (150mM NaCl, 50mM Tris pH7.4, 1mM Ethylenediamine tetraacetic acid (EDTA), 0.5% NP-40). Protein lysate was incubated with StrepTactin resin beads (IBA) and rotated with head-to-tail rotation overnight at 4˚C. The next day, protein-bound beads were washed three times with IP lysis buffer and eluted from the StrepTactin resin with Buffer E (IBA). Eluates were analyzed by immunoblotting as described above.

**Promoter luciferase assays**

HeLa cells seeded at 1x10^5 cells/mL in 12-well or 24-well plates were co-transfected with pNL1.1.TK[Nluc/TK] driving NanoLuc activity, an ISRE-promoter, an IFN-β promoter, or NF-κB promoter driving firefly luciferase activity, SARS-CoV-2 viral proteins (NSP13, NSP1, etc.) or GFP, or Flag-TBK1. Transfections were completed with PolyJet (SignaGen) per manufacturer’s instructions. For assays using SeV as the immune stimulus, 100 HA units/mL were added into media for 16 hours. Cells were harvested at 16 or 24 hours post-transfection, lysed in passive lysis buffer (Promega), and assayed using a Dual Luciferase Reporter Assay System according to manufacturer’s instructions (Promega). Firefly luciferase activity was normalized to NanoLuc activity to account for transfection efficiency. Results represent at least 3 biological replicates.

**Click-iT analysis**

To measure nascent protein synthesis, HeLa cells were plated into 6-well plates and transfected with 1 μg SARS-CoV-2 NSP1 WT, SARS-CoV-2 NSP1 mutant plasmids or SARS-CoV-2 NSP9 the following day. Twenty-four hours post transfection, the existing media was depleted and replenished with methionine-free DMEM (Gibco) supplemented with L-Cysteine (Alfa
Aesar) for one hour. For multiplexes with immunofluorescence, cells were incubated with 100 μM homopropargylglycine (HPG) for 2 hours. Cells were washed once with PBS and then fixed with 4% paraformaldehyde. The Click-iT reaction (Thermo Fisher Scientific) was performed according to the manufacturer’s protocol and immunofluorescence performed as described above. For blots, following methionine depletion, cells were incubated with 50 μM of L-azidohomoalanine (AHA) for one hour. Cells were washed three times with PBS, harvested by centrifugation, and lysed with AHA lysis buffer (1% SDS in 50 mM Tris-HCL, pH 8.0) supplemented with protease inhibitor and 1 U/ml Benzonase Nuclease (Sigma). Protein concentration was determined by Bradford reagent. The Click-iT reaction was performed according to the manufacturer’s protocol with 40–50 μg of total protein. Lysates were run on SDS-PAGE gel as described above.

**Statistical analysis**

One way ANOVA or two way ANOVA were implemented for statistical analysis of the data using GraphPad Prism software. Graphed values are presented as mean ± SD (n = 3 or greater); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.

**Results**

**SARS-CoV-2 infected cells display limited IRF3 and NF-κB nuclear translocation during early time points of infection**

Previous studies have found that SARS-CoV-2 infection elicits a type I interferon response, albeit to differing amounts [22, 25, 29]. To assess the ability of SARS-CoV-2 to trigger immune activation in infected cells, we exposed Calu-3 lung epithelial cells, one of the most permissive cell lines for infection, to SARS-CoV-2 during a time course of infection. At 16, 24, and 48 hours post-infection (hpi), cultures were fixed, permeabilized, and stained for viral nucleocapsid protein to designate SARS-CoV-2 infected cells. Upon RNA virus infection, immune signaling is activated through a multi-step process where pattern recognition receptors recognize intracellular infection resulting in the nuclear translocation of the basally cytoplasmic antiviral transcription factors, IRF3 and NF-κB, an indicator of immune activation [30]. To determine if infected cells were able to block this nuclear translocation, we co-stained for IRF3 (Fig 1A). Nuclear counterstain was used to evaluate nuclear translocation of IRF3 through determining colocalization of DAPI signal with IRF3 in infected cells (Fig 1A). At 16hpi, we found that most infected cells did not cause IRF3 to translocate to the nucleus; instead, we observed this localization change at 48hpi, where approximately 25% of infected cells displayed nuclear localized IRF3 (Fig 1A; white arrows—infected cells without nuclear IRF3, blue arrows—infected cells with nuclear IRF3, quantification Fig 1B). Moreover, we also stained infected cells at 30hpi for the viral Spike protein and contrary to those cells expressing nucleocapsid protein, we observed IRF3 and also NF-κB in the nucleus in cells located adjacent to infected cells, in which limited-to-no viral antigen was detected (S1 Fig). These observations indicate productively infected SARS-CoV-2 cells have limited IRF3 and NF-κB nuclear translocation at 16hpi, but are able to activate some IRF3 at later time points, suggesting a temporal regulation of IFN activation during SARS-CoV-2 infection.

Our data indicate that SARS-CoV-2 can limit interferon activation. To determine the SARS-CoV-2 viral proteins that interfere with the interferon response, we screened 10 of the 16 nonstructural proteins for their ability to limit interferon stimulated response element (ISRE) activation. Sendai virus (SeV) is a known RIG-I-mediated interferon response activator [31], and thus, we stimulated HeLa cells with SeV and measured ISRE promoter activity
through an ISRE-driven luciferase reporter assay. Here, we graphed the relative luciferase units (RLU) as a percentage of a GFP control plasmid and set the RLU obtained in the GFP conditions as 100%. We found that 4 out 10 viral proteins (NSP1, NSP11, NSP13, and NSP14) significantly inhibited the SeV-mediated interferon response, with a reduction of between 25–60% luciferase activity, and with the exception of NSP1 and NSP11, have similar protein expression (Fig 2A and 2B). We proceeded with NSP1 and NSP13 for further immune induction characterization and used NSP9 as a viral protein control as it did not elicit any effect on IFN response (Fig 2A). In addition to inhibiting ISRE promoter activity, NSP1 and NSP13 significantly inhibited SeV-mediated NF-κB promoter activity by approximately 2.5-fold and 2-fold, respectively (Fig 2C). To further affirm restriction of NF-κB promoter activity, we additionally used immunofluorescence and image quantification to investigate antagonism of NF-κB nuclear translocation. While NSP13 significantly inhibited both NF-κB promoter activity and nuclear translocation, rather surprisingly, we found that NSP1 instead had significantly enhanced NF-κB nuclear translocation (Fig 2D and 2E). To further define the role of NSP13 in blocking NF-κB activation, we wanted to directly activate NF-κB using the kinase TBK1. We stimulated HeLa cells with addition of exogenous TBK1 and asked whether NSP13 could block NF-κB activation, as measured by phospho-NF-κB (p-NF-κB) protein levels on an immunoblot. We found that in TBK1 only transfected cells, p-NF-κB was present, but this band was reduced when NSP13 was added, further supporting the role of NSP13 in limiting NF-κB activation (Fig 2F). Since promoter luciferase activity measures a transcription event, distinct from nuclear translocation, we deduced that inhibition must occur after nuclear translocation.
Fig 2. SARS-CoV-2 viral proteins NSP1 and NSP13 limit IFN response promoter and NF-κB activation. (A) Relative ISRE-promoter driven luciferase values of indicated viral proteins and GFP control in HeLa cells 16 hours post-SeV infection. Values depict mean ± SD (n = 3–5 biological replicates) in relative luciferase units (RLU). Data was analyzed by one-way ANOVA; **p < 0.001, ***p < 0.0001. (B) Immunoblot analysis of lysates harvested at 24 hours from HeLa cells transfected with the indicated Strep-tagged SARS-CoV-2 plasmids or GFP. Tubulin is shown as a loading control. Ladder is included as kDa (C) Relative NF-κB-promoter driven luciferase values of indicated viral proteins and GFP control in HeLa cells 16 hours post-SeV infection. Values depict mean ± SD (n = 5 biological replicates) in relative luciferase units (RLU). Data were analyzed by one-way ANOVA; **p ≤ 0.001, and ***p ≤ 0.0001. (D) Representative images of HeLa cells expressing the indicated viral proteins and GFP control were stimulated with SeV infection for 6 hours. Cells were immunostained for anti-NF-κB (red), anti-Strep

NF-κB/IFN response promoter

NF-κB promoter

ISRE promoter

GFP

NSP1

NSP9

NSP13

Strep

Tubulin

% NF-κB nuclear translocation
of transcription regulatory factors, but prior to production of the luciferase signal (i.e. at the level of transcription or translation). Additionally, while NSP13 inhibited NF-κB nuclear translocation, NSP1 did not, suggesting that NSP1 antagonizes a step in the interferon activation pathway proceeding nuclear translocation. As there is precedence for MERS and SARS-CoV NSP1 to inhibit translation [17, 19], we next asked whether SARS-CoV-2 NSP1 inhibits translation.

**SARS-CoV-2 NSP1 thwarts nascent protein synthesis**

Both SARS-CoV and MERS-CoV are known to inhibit host gene expression through NSP1 [17, 19, 20, 32, 33]. Based on previous literature with SARS-CoV and MERS-CoV NSP1, we aligned NSP1 protein sequences of the three related coronaviruses and noted similarities between the two key sets of amino acids identified to be especially important for function (K164/H165 and R124/K125, Fig 3A and [19, 32, 34]). K164/H165 are important for ribosomal binding, while R124/K125 are necessary for RNA cleavage [34]. We mutated these two sets of residues to alanines as this residue change has been previously described to perturb the viral antagonism function in these related coronaviruses and introduced these two sets of mutants into SARS-CoV-2 NSP1 [19, 33]. We next determined the impact of wild-type (WT) and mutant NSP1 on nascent protein synthesis using metabolic labeling and click-chemistry multiplexed with immunofluorescent staining of HeLa cells transfected with GFP, NSP9, NSP1, or NSP1 mutants. We found that new protein synthesis was abolished in cells that expressed WT NSP1 (Fig 3B). This phenotype was completely reversed with the NSP1KH mutant, but not with the NSP1RK mutant, suggesting that the inhibition of nascent protein production by SARS-CoV-2 is independent of its RNA cleavage ability. This finding was further substantiated with the more traditional format, using metabolic-labeling, click chemistry and western blot in HeLa cells (Fig 3C).

**SARS-CoV-2 NSP13 reduces TBK1 and IRF3 phosphorylation**

Our results suggest that NSP13 targets both IRF3 and NF-κB activation. We next sought to determine the mechanism of this targeting. TBK1 is a regulatory kinase that functions in multiple innate immune pathways and can signal through both IRF3 and NF-κB. NSP13 has been reported to bind to TBK1 [24, 28]. Given that TBK1 is involved in several signaling pathways, including IFN induction and subsequent IFN signaling, we hypothesized that NSP13 may inactivate TBK1 function, possibly by binding to TBK1, as TBK1 was predicted to be an NSP13-interacting protein in a recent protein interaction study]. To test whether NSP13 interacts with TBK1, we performed an immunoprecipitation with overexpressed NSP13 and TBK1 and found that NSP13 interacts with TBK1 (Fig 4A). We then asked whether the interaction of TBK1 with NSP13 abrogated TBK1 function. To test if NSP13 inhibited IFN activation and the downstream IFN response following TBK1 stimulus, we assessed IFN-β and ISRE-promoter activity in an NSP13-dose responsive manner. Indeed, we found that NSP13 was able to antagonize both the TBK1-induced IFN-β and ISRE promoter activity in a dose-dependent fashion (Fig 4B and 4C). To validate this observation, cell lysates from the same samples in Fig 4A were immunoblotted and probed for protein expression of the ISG, IFIT1, one of several
TBK1-target genes [35]. We found a dose-dependent reduction in IFIT1 protein expression with increasing amounts of NSP13, phenocopying our ISRE promoter luciferase assay (Fig 4D). This suggests that NSP13 could restrict the downstream IFN response by inhibiting...
TBK1 phosphorylation. We observed that phospho-TBK1 (p-TBK1) and phospho-IRF3 (p-IRF3) protein levels were reduced in an NSP13-dose dependent manner, suggesting that NSP13 can limit TBK1 and IRF3 activation (Fig 4D). Taken together, these data suggest that NSP13 may limit TBK1 activation by binding to it and possibly interfering with TBK1 downstream function.

Discussion

Our results highlight that SARS-CoV-2 employs distinct mechanisms to evade immune activation. Here, we show (1) during SARS-CoV-2 infection, IRF3 and NF-κB nuclear translocation is blocked in infected cells at early time points of infection (Fig 1 and S1 Fig); (2) the host
shutoff factor, nonstructural protein 1 (NSP1) blocks IFN and NF-κB promoter activation but is unable to block SeV-mediated NF-κB nuclear translocation (Fig 2); (3) this apparent discrepancy is likely due to the ability of NSP1 to shutdown mRNA translation, which may allow for NF-κB nuclear translocation while limiting NF-κB promoter activation (Fig 3); (4) the viral helicase NSP13 evades IFN and NF-κB responses at the level of TBK1 activation (Fig 4).

Several groups have recently noted that the NSP1 residues K164 and H165 are important for protein translation inhibition for both SARS-CoV-2 and SARS-CoV [20, 24]. Additionally, Xia and colleagues very recently found that NSP13 inhibits TBK1 phosphorylation and subsequent IFN-induction and signaling [24]. Our study adds to this growing literature of SARS-CoV-2 immune evasion mechanisms by identifying that in addition to blocking IRF3-mediated IFN activation, NSP13 is also capable of obstructing NF-κB activation, suggesting that NSP13 may play a role in regulating multiple innate immune pathways during SARS-CoV-2 infection.

Our study explores immune activation, using IRF3 and NF-κB as a read-out, in the context of full virus infection. SARS-CoV-2 has several proteins that have been shown to block IFN induction [21, 24, 25]. It remains to be seen how these proteins coordinate inhibition of immune activation and which features of each viral protein guide these immune functions. NSP13 may have a role in blocking NF-κB responses that is independent of its interaction with TBK1. Indeed, a previous study identified that NSP13 may interact with TLE1 [28], a known NF-κB signaling interactor [36]. Additionally, our study did not examine downstream NF-κB-dependent gene expression in the context of NSP1 overexpression. It is possible that the reduction in downstream NF-κB promoter activity yet increased nuclear translocation during NSP1 overexpression may be due to blocking induction of these NF-κB-dependent genes.

Our study examined NSP13 function during overexpression. NSP13 is a member of the viral replication complex for SARS-CoV [37] and SARS-CoV-2 [38, 39]. We did not examine whether NSP13 localization extends beyond that of the replication complex in the context of viral infection. Thus, single protein overexpression may not fully recapitulate what is observed during full-length virus infection. Examination of the mechanisms utilized by SARS-CoV NSP13 may inform studies on SARS-CoV-2 NSP13 research as the amino acid sequences of both viral NSP13 proteins are nearly identical and diverge at only one amino acid residue [40]. Future research should be aimed at exploring other NSP13-protein interactions that may dictate immune responses and potential disease outcomes during SARS-CoV-2 infection. We have shown a role of NSP13 in blocking TBK1 activation, downstream IRF3 activation, and IFIT1 protein expression (Fig 4). Interestingly, while the protein expression levels of both phospho-IRF3 and IFIT1 are drastically reduced, the difference in protein expression levels of phospho-TBK1 is not as stark. Last, our study did not examine the role of NSP13 in limiting interferon signaling through the JAK/STAT pathway, and thus we cannot eliminate the possibility that NSP13 may be limiting both IFN-β induction and signaling. To this point, a recent study by Lei and colleagues has found that indeed NSP13 plays a role in both branches of the RIG-I-mediated innate immune pathway [25].

Recently published papers have provided structural and mechanistic insight into NSP1 translation inhibition by defining the NSP1 residues that govern this translation inhibition, that NSP1 binds to the 40S ribosomal subunit, and these events lead to subsequent immune evasion by reducing interferon mRNA expression [21, 26]. Our work supports the role of NSP1 in inhibiting translation using Click-iT chemistry [41], an assay that further validates and complements those used in these studies. It is worth noting that while our study suggests that the mechanism of translation inhibition is likely through ribosomal binding, our data do not address the exact role of the enzymatic activity of NSP1 in reducing nascent protein synthesis. Instead, however, work done by several other groups, has shown that NSP1 acts by
ribosomal binding [21, 23, 26]. Future studies should examine the RNA cleavage capacity of
NSP1 and whether that affects subsequent protein translation.

We did not explore the role of all SARS-CoV-2 proteins in immune signaling evasion. It is
possible other SARS-CoV-2 proteins can redundantly bypass IRF3 and NF-κB responses.
Indeed, Xia and colleagues describe that several viral proteins, including the M protein, ORF6,
and ORF7a inhibit type I IFN signaling [24]. It is known that the SARS-CoV M protein sup-
presses the antiviral response, and thus SARS-CoV-2 may likely antagonize antiviral signaling
through similar mechanisms [42]. Taken together, our research defines a role for the SARS-
CoV-2 NSP1 and NSP13 viral proteins in evading host interferon activation through distinct
mechanisms.

Supporting information

S1 Fig. IRF3 and NF-κB nuclear translocation during SARS-CoV-2 infection of Calu-3
lung epithelial cells. (A, C) Representative image of Calu-3 cells 30 hours post SARS-CoV-2
infection that were immunostained with anti-Spike SARS-CoV-2 (green), anti-IRF3 (A, red),
or anti-NF-κB (C, red). Nuclei are counterstained with DAPI (blue) with nuclear translocation
of IRF3 (A) or NF-κB (C) visualized through co-localization of DAPI signal with IRF3 (A) or
NF-κB (C). White arrows point to neighboring cells that have nuclear translocation of IRF3
(A) or NF-κB (C). Light blue arrows point to infected cells that are activated for IRF3 tran-
scription (A) or NF-κB (C). Scale bar: 50 μm. (B) Quantification of images from (A) with cells
positive for SARS-CoV-2 that had nuclear translocation of IRF3. Data are displayed as
mean ± SD (n = 5 images counted with at least 50 cells per image). Data were analyzed by one-
way ANOVA; ****p < 0.0001 (D). Quantification of images from (C) with cells positive for
SARS-CoV-2 that had nuclear translocation of NF-κB. Data are displayed as mean ± SD (n = 5
images counted with at least 50 cells per image). Data were analyzed by one-way ANOVA;
****p < 0.0001.

(TIF)

S1 File.

(PPTX)

Acknowledgments

We would like to thank members of the Jurado lab for helpful discussion and critical reading
of the manuscript. We would also like to extend gratitude to Dr. Sunny Shin for helpful discus-
sion. This research used a HeLa cell line, and therefore we would like to acknowledge Hen-
rietta Lacks. The HeLa cell line that was established from her tumor cells without her
knowledge or consent in 1951 has made significant contributions to scientific progress and
advances in human health. We are grateful to Henrietta Lacks, now deceased, and to her sur-
viving family members for their contributions to biomedical research.

Author Contributions

Conceptualization: Christine Vazquez, Kellie A. Jurado.

Data curation: Christine Vazquez, Sydnie E. Swanson, Seble G. Negatu, Kellie A. Jurado.

Formal analysis: Christine Vazquez, Sydnie E. Swanson, Seble G. Negatu, Kellie A. Jurado.

Funding acquisition: Kellie A. Jurado.
Investigation: Christine Vazquez, Mark Dittmar, Jesse Miller, Holly R. Ramage, Sara Cherry, Kellie A. Jurado.

Methodology: Christine Vazquez, Sydnie E. Swanson, Kellie A. Jurado.

Supervision: Kellie A. Jurado.

Visualization: Christine Vazquez, Sydnie E. Swanson, Kellie A. Jurado.

Writing – original draft: Christine Vazquez, Sydnie E. Swanson, Kellie A. Jurado.

References

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet (London, England). 2020; 395(10223):470–3. https://doi.org/10.1016/S0140-6736(20)30185-9 PMID: 31986257

2. Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet (London, England). 2003; 362(9393):1353–8. https://doi.org/10.1016/S0140-6736(03)14630-2 PMID: 14585636

3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England journal of medicine. 2012; 367(19):1814–20. https://doi.org/10.1056/NEJMoa121721 PMID: 23075143

4. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265–9. https://doi.org/10.1038/s41586-020-2008-3 PMID: 32015508

5. Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011; 34(5):680–92. https://doi.org/10.1016/j.immuni.2011.05.003 PMID: 21616437

6. Hiscott J, Pitha P, Genin P, Nguyen H, Heylbroeck C, Mamane Y, et al. Triggering the interferon response: the role of IRF-3 transcription factor. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 1999; 19(1):1–13. https://doi.org/10.1089/107999099314360 PMID: 10048763

7. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nature immunology. 2003; 4(5):491–6. https://doi.org/10.1038/ni921 PMID: 12692549

8. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science (New York, NY). 2002; 296(5573):1653–5. https://doi.org/10.1126/science.1071545 PMID: 12040185

9. Ahmad L, Zhang SY, Casanova JL, Sancho-Shimizu V. Human TBK1: A Gatekeeper of Neuroinflammation. Trends in molecular medicine. 2016; 22(6):511–27. https://doi.org/10.1016/j.molmed.2016.04.006 PMID: 27211305

10. Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-kB: A Blossoming of Relevance to Human Pathobiology. Cell. 2017; 168(1–2):37–57. https://doi.org/10.1016/j.cell.2016.12.012 PMID: 28086098

11. Rabouw HH, Langereis MA, Knaap RC, Dalebout TJ, Canton J, Sola I, et al. Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses. PLoS pathogens. 2016; 12(10):e1005982. https://doi.org/10.1371/journal.ppat.1005982 PMID: 27783669

12. Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, et al. Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. Journal of virology. 2014; 88(9):4866–76. https://doi.org/10.1128/JVI.03649-13 PMID: 24522921

13. Spiegel M, Pichlmair A, Martinez-Sobrido L, Cros J, Garcia-Sastre A, Haller O, et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. Journal of virology. 2005; 79(4):2079–86. https://doi.org/10.1128/JVI.79.4.2079-2086.2005 PMID: 15681410

14. Yang Y, Ye F, Zhu N, Wang W, Deng Y, Zhao Z, et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. Scientific reports. 2015; 5:17554. https://doi.org/10.1038/srep17554 PMID: 26631542

15. Matthews KL, Coleman CM, van der Meer Y, Snijder EJ, Frieman MB. The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. The Journal of general virology. 2014; 95(4):874–82. https://doi.org/10.1099/vir.0.062059-0 PMID: 24443473
16. Siu KL, Kok KH, Ng MH, Poon VK, Yuen KY, Zheng BJ, et al. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3-TANK-TBK1/IKK epsilon complex. The Journal of biological chemistry. 2009; 284(24):16202–9. https://doi.org/10.1074/jbc.M109.008227 PMID: 19380580

17. Kamitani W, Huang C, Narayanan K, Lokugamage KG, Makino S. A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nap1 protein. Nature structural & molecular biology. 2009; 16(11):1134–40. https://doi.org/10.1038/nsmb.1680 PMID: 19831910

18. Lokugamage KG, Narayanan K, Nakagawa K, Terasaki K, Ramirez SI, Tseng CT, et al. Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin. Journal of virology. 2015; 89(21):10970–81. https://doi.org/10.1128/JVI.01352-15 PMID: 26311885

19. Narayanan K, Huang C, Lokugamage K, Kamitani W, Iketami T, Tseng CT, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. Journal of virology. 2008; 82(9):4471–9. https://doi.org/10.1128/JVI.02472-07 PMID: 18305050

20. Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(34):12885–90. https://doi.org/10.1073/pnas.0603144103 PMID: 16912115

21. Thoms M, Buschauer R, Ameismeier M, Koepple L, Denk T, Hirschenberger M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science (New York, NY). 2020. https://doi.org/10.1126/science.abc8665 PMID: 32680882

22. Shuai H, Chu H, Hou Y, Yang D, Wang Y, Hu B, et al. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer. The Journal of infection. 2020; 81(4):e1–e10. https://doi.org/10.1016/j.jinf.2020.07.016 PMID: 32707230

23. Schubert K, Karoukis ED, Jomaa A, Scaiola A, Echeverria B, Gurzeler LA, et al. SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nature structural & molecular biology. 2020; 27(10):959–66.

24. Xia H, Cao Z, Xie X, Zhang X, Chen YJ, Wang H, et al. Evasion of Type I Interferon by SARS-CoV-2. Cell reports. 2020; 33(1):108234. https://doi.org/10.1016/j.celrep.2020.108234 PMID: 32979938

25. Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nature communications. 2020; 11(1):3810. https://doi.org/10.1038/s41467-020-17665-9 PMID: 32733001

26. Banerjee AK, Bianco MR, Bruce EA, Honson DD, Chen LM, Chow A, et al. SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses. Cell. 2020.

27. Gey GO, Coffman W. D., and Kubicek M. T. Tissue Culture Studies of the Proliferative Capacity of Cervical Carcinoma and Normal Epithelium. Cancer Res. 1952; 12:264–5.

28. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020.

29. Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus research. 2020; 286:198074. https://doi.org/10.1016/j.virusres.2020.198074 PMID: 32589897

30. Chiang HS, Liu HM. The Molecular Basis of Viral Inhibition of IRF- and STAT-Dependent Immune Responses. Frontiers in immunology. 2018; 9:3086. https://doi.org/10.3389/fimmu.2018.03086 PMID: 30670585

31. Sumpter R Jr., Loo YM, Foy E, Li K, Yoneyama M, Fujita T, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. Journal of virology. 2005; 79(5):2689–99. https://doi.org/10.1128/JVI.79.5.2689-2699.2005 PMID: 15708988

32. Lokugamage KG, Narayanan K, Huang C, Makino S. Severe acute respiratory syndrome coronavirus protein nsp1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation. Journal of virology. 2012; 86(24):13598–608. https://doi.org/10.1128/JVI.01958-12 PMID: 23035226

33. Tanaka T, Kamitani W, DeDiego ML, Enjuanes L, Matsuura Y. Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA. Journal of virology. 2012; 86(20):11128–37. https://doi.org/10.1128/JVI.01700-12 PMID: 22855488
34. Terada Y, Kawachi K, Matsuura Y, Kamitani W. MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA. Virology. 2017; 511:95–105. https://doi.org/10.1016/j.virol.2017.08.026 PMID: 28843094

35. Goncalves A, Bürckstümmer T, Dixit E, Scheicher R, Görna MW, Karayel E, et al. Functional dissection of the TBK1 molecular network. PloS one. 2011; 6(9):e23971. https://doi.org/10.1371/journal.pone.0023971 PMID: 21931631

36. Ramasamy S, Saez B, Mukhopadhyay S, Ding D, Ahmed AM, Chen X, et al. Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113(7):1871–6. https://doi.org/10.1073/pnas.1513801113 PMID: 26831087

37. Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. Journal of virology. 2004; 78(11):5619–32. https://doi.org/10.1128/JVI.78.11.5619-5632.2004 PMID: 15140959

38. Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinares PDB, et al. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex. Cell. 2020; 182(6):1560–73.e13. https://doi.org/10.1016/j.cell.2020.07.033 PMID: 32783916

39. Yan L, Zhang Y, Ge J, Zheng L, Gao Y, Wang T, et al. Architecture of a SARS-CoV-2 mini replication and transcription complex. Nature communications. 2020; 11(1):5874. https://doi.org/10.1038/s41467-020-19770-1 PMID: 33208736

40. White MA, Lin W, Cheng X. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase. The journal of physical chemistry letters. 2020; 11:9144–51. https://doi.org/10.1021/acs.jpclett.0c02421 PMID: 33052685

41. Kolb HC, Finn MG, Sharpless KB. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angewandte Chemie (International ed in English). 2001; 40(11):2004–21. https://doi.org/10.1002/1521-3773(20010601)40:11<2004::aid-anie200403330>3.0.co;2-x PMID: 11433435

42. Siu KL, Chan CP, Kok KH, Chiu-Yat Woo P, Jin DY. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cellular & molecular immunology. 2014; 11(2):141–9. https://doi.org/10.1038/cmi.2013.61 PMID: 24509444